|Other Names||Secretoglobin family 1D member 2, Lipophilin-B, SCGB1D2, LIPHB, LPNB|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP13793c was selected from the Center region of SCGB1D2. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||May bind androgens and other steroids, may also bind estramustine, a chemotherapeutic agent used for prostate cancer. May be under transcriptional regulation of steroid hormones.|
|Tissue Location||Highest expression was found in skeletal muscle. Expressed as well in thymus, trachea, kidney, steroid responsive tissues (prostate, testis, uterus, breast and ovary) and salivary gland|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The protein encoded by this gene is a member of thelipophilin subfamily, part of the uteroglobin superfamily, and isan ortholog of prostatein, the major secretory glycoprotein of therat ventral prostate gland. Lipophilin gene products are widelyexpressed in normal tissues, especially in endocrine-responsiveorgans. Assuming that human lipophilins are the functionalcounterparts of prostatein, they may be transcriptionally regulatedby steroid hormones, with the ability to bind androgens, othersteroids and possibly bind and concentrate estramustine, achemotherapeutic agent widely used for prostate cancer. Althoughthe gene has been reported to be on chromosome 10, this sequenceappears to be from a cluster of genes on chromosome 11 thatincludes mammaglobin 2.
Sjodin, A., et al. Anticancer Res. 28 (3A), 1493-1498 (2008) :Culleton, J., et al. Int. J. Cancer 120(5):1087-1092(2007)Sjodin, A., et al. Acta Neuropathol. 109(4):381-386(2005)Carter, D., et al. Clin. Cancer Res. 9(2):749-754(2003)Carter, D., et al. Biochemistry 41(21):6714-6722(2002)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.